ONCOLOGY
Over the last 3 years, Encorium has been involved in more than 40 oncology studies at over 400 international sites in 23 countries. Expertise ranges from first-in-man through pivotal phase III and IV studies.
We have access to extensive networks of physician-investigators in North America, Western Europe, Central & Eastern Europe, Scandinavia and The Baltics. In the therapeutic area of GU Oncology and Urology alone we have more than 2,000 experienced investigators and have conducted 10 prostate cancer trials.
Encorium have experience with the following compound classes and treatments:
- Antibodies
- Anti-emetics
- Autologous T-cells
- Bone-marrow transplant
- Cytotoxic Chemotherapy including Alkylating agents, Taxanes,
Topoisomerase inhibitors, PARP Inhibitors and Platinum Compounds
- Hormonal Therapeutics
- Radiotherapy
- Recombinant Adenovirus
- Stem cell transplant
Indications:
- Breast Cancer
- Head and Neck Cancer
- Prostate Cancer
- Ovarian Carcinoma
- Colorectal Cancer
- Recurrent Gastric Cancer
- Carcinoid Tumor of G.I. tract
- Renal Cell Carcinoma
- Bladder Cancer
- Urethral Cancer
- Pancreatic Cancer
- Small Cell Lung Cancer
|
- Non Small Cell Lung Cancer
- HIV related cancers
- Mesothelioma
- Myeloma
- Lymphoma
- Non-Hodgkin’s Lymphoma
- Chronic Follicular Lymphoma
- Acute Myelogenous Leukaemia
- Chronic Myelogenous Leukaemia
- Chronic Lymphocytic Leukaemia
- Chemotherapy induced anaemia
- Treatment Refractory Solid Tumor
|
|
